Dr. Reddy’s completes Phase 1 study of proposed biosimilar of tocilizumab
Dr. Reddy’s Laboratories shares gained on Monday in the backdrop of the drugmaker announcing successful completion of a phase-1 study of its proposed biosimilar of tocilizumab for use in the treatment of rheumatoid arthritis. DRL_TC, the biosimilar candidate, successfully met its primary and secondary endpoints in a Phase 1 study that used a subcutaneous formulation […]
Continue Reading
